Market Newsdesk

Vocational school, community colleges receiving grants

HOLMDEL, N.J.
, Nov. 14, 2025 /PRNewswire/ — To inspire the next generation of electric industry professionals, the FirstEnergy Foundation is donating $55,000 to New Jersey educational programs focused on electrical trades and science, technology, engineering and mathematics (STEM) programming. The grants are part of more than $5.5 million in community support distributed across FirstEnergy’s service area to date in 2025.

Five vocational school and community college programs, located in communities served by FirstEnergy (NYSE: FE) electric company Jersey Central Power & Light (JCP&L), are directly benefiting from the donations.

Filling A Future Need
The FirstEnergy Foundation grants will support a variety of electrical education and STEM programs that benefit students at all levels, from elementary school through college.

Doug Mokoid, FirstEnergy’s President of New Jersey: “We live in an increasingly connected, high-tech society. We need to prepare the next generation to meet those demands, whether they are working on electrical systems, flying drones or engineering the next great device. STEM is a vital part of the future. New Jersey has been at the center of innovation since the invention of the light bulb, and we’re proud to help continue that great tradition in the communities we serve.”

Funding The Future
Programs receiving grants include:

• 
  Brookdale Community College Foundation Trust, Monmouth County($20,000): Funding will enhance seven electrical engineering lab stations used by more than 230 students for courses such as electronics, digital logic, industrial automation and embedded systems, circuit design and analysis, signal generation and measurement, safe power delivery and adjustable voltage testing.
• Warren County College Foundation, Warren County($15,000): The grant funds the Readiness Initiative for Safety & Education (RISE) program’s drone training program, which works with local schools and police to offer free drone operator training and pilot certificates. Through RISE, 20 high school educators and 10 police officers will earn their FAA Part 107 Remote Pilot Certificate each year.
• 
  Sussex County Community College, Sussex County($10,000): Funds will establish a program to loan tools to the 30 students enrolled in the college’s Electrical Line Worker program and buy electrical safety gear for low-income students.
• 
  Ocean County College Foundation, Ocean County($5,000): Funding supports the Cosmos Classroom program at the Robert J. Novins Planetarium, delivering science and STEM education to almost 8,000 K-12 students annually through 160 public, private and home school field trips and community partnerships.
• Ocean County Foundation for Vocational and Technical Education ($5,000): Funding will help provide electrical supplies for nearly 150 students in the Electrical Trade Technology program’s simulated work environment.

More Than Money
Earlier this year, JCP&L volunteers participated in Career Day activities at Ocean County Vocational and Technical School, sharing their experience and expertise with students in the Electrical Trade Technology program. The company also regularly hosts STEM groups from local schools at its Holmdel and Morristown headquarters, providing an inside glimpse into the management of the electrical grid.

How to Apply for a FirstEnergy Foundation Grant in New Jersey

The FirstEnergy Foundation provides support to 501(c)(3) tax-exempt nonprofits that serve and meet the critical needs of our customers in communities served by JCP&L and FirstEnergy’s electric operating companies and in areas where the company conducts business.

The FirstEnergy Foundation does not accept unsolicited grant applications. To inquire about grant opportunities, contact Alix Hayes, Community Involvement Consultant at [email protected].

JCP&L serves 1.2 million customers in the counties of Burlington, Essex, Hunterdon, Mercer, Middlesex, Monmouth, Morris, Ocean, Passaic, Somerset, Sussex, Union and Warren. Follow JCP&L on X @JCP_L, on Facebook at facebook.com/JCPandL or online at jcp-l.com.

FirstEnergy is dedicated to integrity, safety, reliability and operational excellence. Its electric distribution companies form one of the nation’s largest investor-owned electric systems, serving more than six million customers in Ohio, Pennsylvania, New Jersey, West Virginia, Maryland and New York. The company’s transmission subsidiaries operate approximately 24,000 miles of transmission lines that connect the Midwest and Mid-Atlantic regions. Follow FirstEnergy on X @FirstEnergyCorp or online at firstenergycorp.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/firstenergy-foundation-energizing-the-future-of-stem-electrical-trades-302615912.html

SOURCE FirstEnergy Corp.

• Film captures inspiring journeys of three individuals living with chronic lymphocytic leukemia (CLL)
• CLL is one of the most common leukemias among adults affecting more than 200,000 people in the United States^1,2
• Film premiered yesterday in Los Angeles, hosted by actor and advocate Jesse Tyler Ferguson
• Now available on LA Times Studio Short Docs, AbbVie U.S. YouTube Channel; streaming on Documentary+ in December

NORTH CHICAGO, Ill.
, Nov. 14, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today the launch of Second Winds, a new short film that captures the powerful, deeply personal journeys of three people living with chronic lymphoma leukemia (CLL), a common type of blood cancer effecting hundreds of thousands of people in the United States.^1,2 Each person’s dynamic story reveals how facing a life-changing diagnosis can bring clarity and purpose, sparking a renewed commitment to staying active and embracing what truly matters in their lives.

Second Winds follows three inspiring subjects: Christina, who was diagnosed in 2013 and now leads peer support groups for newly diagnosed CLL patients; Jeff, a retiree who has lived with CLL for two decades; and Alejandro, an environmental engineer and father of three who was diagnosed in 2020. Through their stories, the film explores how, with the unwavering support of their families and communities, they found not only strength but the inspiration to survive and keep pursuing the activities they love, from hiking and cycling to snow skiing and land paddling.

“Second Winds shines a powerful light on the resilience and hope of people living with chronic lymphocytic leukemia,” said Andy Souers, Ph.D., VP and distinguished research fellow, Oncology Discovery Research, AbbVie. “At AbbVie, we support the blood cancer community, not only through scientific innovation to develop treatments that address the disease and a person’s quality of life, but also by amplifying their inspiring stories.”

Second Winds had its premiere on November 13 in Los Angeles, hosted by Jesse Tyler Ferguson, an award-winning actor, producer, and author.

“Cancer has touched my own family, so I know firsthand how deeply it can impact one’s perspective on life,” said Ferguson. “What moved me about Second Winds is that it shows even in the face of a devastating diagnosis, people can rediscover purpose and joy. Hosting this film premiere felt like a way to honor that strength and resilience.”

Second Winds was directed by award-winning filmmaker Dominic Gill (Planetwalker, Last Call for the Bayou) from Encompass Films who was shortlisted for an Oscar this year.

“Spending time with the films’ subjects gave me a unique perspective on what it means to be a survivor,” said Gill. “By working alongside the filmmaking team, and having AbbVie as a partner, I was able to bring light to how determination and hope can truly make a difference. I’m honored to have directed this film and to show the world these amazing stories of perseverance.”

Second Winds is supported by AbbVie as part of its ongoing commitment to help those affected by CLL. CLL is one of the most common forms of leukemia in adults and is a type of cancer that develops from cells in the bone marrow that later mature into certain white blood cells (called lymphocytes).¹ While these cancer cells start in the bone marrow, they later spread into the blood.¹ In 2022, there were approximately 226,432 people with CLL living in the United States with more than 23,000 new cases expected in 2025.² CLL is more common in older Caucasian males with a median age at diagnosis of 65 to 74 years and only 11-13% of known cases reported in non-Caucasian populations.^3,4

The film is now available on LA Times Studios Short Docs and AbbVie’s YouTube Channel. It will be available to stream on Documentary+ starting December 2025.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

About AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

References

1. American Cancer Society. Leukemia – Chronic Lymphocytic Leukemia. https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/what-is-cll.html. Accessed October 2025.
2. National Cancer Institute. Cancer Stat Facts: Leukemia — Chronic Lymphocytic Leukemia (CLL). https://seer.cancer.gov/statfacts/html/clyl.html. Accessed October 2025.
3. Shanafelt, et al. Age at Diagnosis and the Utility of Prognostic Testing in Patients with Chronic Lymphocytic Leukemia (CLL). Cancer. 2010; 116(20): 4777–4787.
4. Vardell, et al. Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. Am J Hematol. 2023. doi:10.1002/ajh.26937.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-partners-with-award-winning-filmmaker-on-film-about-the-dynamic-and-resilient-lives-of-those-living-with-blood-cancer-302615908.html

SOURCE AbbVie

MEMPHIS, Tenn., Nov. 14, 2025 /PRNewswire/ — International Paper (NYSE: IP; LSE: IPC) today announced the closure of its packaging facilities in Compton, California and Louisville, Kentucky. The facilities will cease operations by January 2026. All customers will be serviced from other nearby locations.

The Compton facility closure will impact 125 employees, while the Louisville facility closure will impact 93 employees. The company will work to minimize the impact on employees by using attrition, retirements and current vacancies at other International Paper locations. Team members at these locations will receive outplacement assistance, access to mental health support resources and severance benefits.

“Making the decision to close a facility is incredibly difficult, especially knowing the impact it has on our team members and their families,” said Tom Hamic, executive vice president and president, North American Packaging Solutions, International Paper. “We are sincerely grateful for the contributions of our departing team members, and we are fully committed to supporting them through this transition.”

International Paper is undergoing a transformational journey to become a stronger sustainable packaging solutions company. A critical step in this journey is to streamline IP’s footprint to focus investments on facilities that will best serve customers and accelerate strategic initiatives to improve quality, reliability and service delivery.

About International Paper
International Paper (NYSE: IP; LSE: IPC) is the global leader in sustainable packaging solutions. With company headquarters in Memphis, Tennessee, USA, and EMEA (Europe, Middle East and Africa) headquarters in London, UK, we employ more than 65,000 team members and serve customers around the world with operations in more than 30 countries. Together with our customers, we make the world safer and more productive, one sustainable packaging solution at a time. Net sales for 2024 were $18.6 billion. In 2025, International Paper acquired DS Smith creating an industry leader focused on the attractive and growing North American and EMEA regions. Additional information can be found by visiting internationalpaper.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/international-paper-announces-closures-of-compton-california-and-louisville-kentucky-packaging-facilities-as-part-of-strategic-growth-initiative-in-north-america-302615907.html

SOURCE International Paper

BENSALEM, Pa.
, Nov. 14, 2025 /PRNewswire/ — The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against James Hardie Industries plc (“James Hardie” or the “Company”) (NYSE: JHX).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN JAMES HARDIE INDUSTRIES PLC (JHX),
CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE DECEMBER 23, 2025
(LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?
The complaint filed alleges that, between May 20, 2025 and August 18, 2025, Defendants failed to disclose to investors that: (1) sales in James Hardie’s largest business segment were experiencing inventory loading by channel partners, with the hallmarks of fraudulent channel stuffing, and not sustainable customer demand as represented; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

View original content:https://www.prnewswire.com/news-releases/james-hardie-industries-plc-jhx-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302615780.html

SOURCE Law Offices of Howard G. Smith

LOS ANGELES
, Nov. 14, 2025 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with losses related to aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATYR PHARMA INC. (ATYR), CLICK HERE BEFORE DECEMBER 8, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

What Is The Lawsuit About? 
The complaint filed alleges that, between November 7, 2024 and September 12, 2025, Defendants failed to disclose to investors that: (1) Defendants created adverse facts concerning aTyr’s study design for EFZO-FIT, giving the false impression that Efzofitimod would meet its primary endpoint; (2) Defendants crafted a narrative that the Phase 3 EFZO-FIT study would provide a way for patients to fully remove steroids from their treatment plans; (3) there may be other factors that permit patients to completely remove steroids from their treatment plans; (4) thus, their Phase 3 EFZOFIT study failed to meet the primary endpoint in change from baseline in mean daily OCS dose at week 48; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz,
Telephone: 310-914-5007
Email: [email protected]
Visit our website at: www.frankcruzlaw.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/atyr-pharma-inc-atyr-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302615846.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

LOS ANGELES
, Nov. 14, 2025 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with losses related to CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CARMAX, INC. (KMX), CLICK HERE BEFORE JANUARY 2, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

 What Is The Lawsuit About?
The complaint filed alleges that, between June 20, 2025 and November 5, 2025, Defendants failed to disclose to investors that: (1) Defendants recklessly overstated CarMax’s growth prospects when, in reality, its earlier growth in the 2026 fiscal year was a temporary benefit from customers buying cars due to speculation regarding tariffs; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View original content to download multimedia:https://www.prnewswire.com/news-releases/carmax-inc-kmx-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302615842.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

LOS ANGELES
, Nov. 14, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH).

IF YOU SUFFERED A LOSS ON YOUR MOLINA INVESTMENTS, CLICK HERE BEFORE DECEMBER 2, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed alleges that, between February 5, 2025 and July 23, 2025, Defendants failed to disclose to investors: (1) material, adverse facts concerning the Company’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224) 
Visit our website at www.glancylaw.com.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Glancy Prongay & Murray LLP,  
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/molina-healthcare-inc-moh-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302615829.html

SOURCE Glancy Prongay & Murray LLP

BENSALEM, Pa.
, Nov. 14, 2025 /PRNewswire/ — The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Marex Group plc (“Marex” or the “Company”) (NASDAQ: MRX).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MAREX GROUP PLC (MRX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE DECEMBER 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?
The complaint filed alleges that, between May 16, 2024 and August 5, 2025, Defendants failed to disclose to investors that: (1) the Company sold over-the-counter financial instruments to itself; (2) Marex had inconsistencies in its financial statements between its subsidiaries and related parties, including as to intercompany receivables and loans; (3) as a result of the foregoing, Marex’s financial statements could not be relied upon; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

View original content:https://www.prnewswire.com/news-releases/marex-group-plc-mrx-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302615796.html

SOURCE Law Offices of Howard G. Smith

BENSALEM, Pa.
, Nov. 14, 2025 /PRNewswire/ — The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CYTOKINETICS, INCORPORATED (CYTK),
CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE NOVEMBER 17, 2025
(LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?
The complaint filed alleges that, between December 27, 2023 and May 6, 2025, Defendants failed to disclose to investors that: (1) Defendants had knowingly or recklessly omitted a REMS from the initial NDA submission, despite prior FDA discussions about safety and risk mitigation; (2) the subsequent REMS submission necessitated a three-month delay in the FDA’s process for potential approval; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847
[email protected]
www.howardsmithlaw.com

View original content:https://www.prnewswire.com/news-releases/cytokinetics-incorporated-cytk-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302615809.html

SOURCE Law Offices of Howard G. Smith

LOS ANGELES
, Nov. 14, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX).

IF YOU SUFFERED A LOSS ON YOUR MOONLAKE INVESTMENTS, CLICK HERE
BEFORE DECEMBER 15, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed alleges that, between March 10, 2024 and September 29, 2025, Defendants failed to disclose to investors that: (1) that SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) that SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More: 
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/moonlake-immunotherapeutics-mltx-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302615808.html

SOURCE Glancy Prongay & Murray LLP